Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3076 to 3090 of 8314 results

  1. Good practice guidance – Integrated process statement (PMG12)

    This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance

  2. Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)

    This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs

  3. Interim clinical guideline surveillance process and methods guide 2013 (PMG16)

    This guide outlines the main elements of the interim NICE clinical guideline surveillance process and methodology, which was agreed by the NICE Board in July 2013

  4. Guide to the technology appraisal and highly specialised technologies appeal process (pre June 2023) (PMG18)

    This document concerns the appeal process for the technology appraisal and highly specialised technologies programmes and provides an overview for organisations wishing to lodge an appeal

  5. Guide to the processes of technology appraisal (PMG19)

    This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes

  6. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs

  7. Guide to the methods of technology appraisal 2013 (PMG9)

    This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process

  8. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at moderately increased risk

    Page 1 of 19 Taking a medicine to reduce the chance of developing breast cancer Decision aid for postmenopausal women at moderately increased

  9. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    Page 1 of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at high risk Published

  10. Bisphosphonates for treating osteoporosis. Patient decision aid on bisphosphonates for treating osteoporosis

    Bisphosphonates for treating osteoporosis Patient decision aid What is osteoporosis and how can bisphosphonates help? Everyone's bones get weaker as...

  11. Kidney conditions: CKD and SGLT2 inhibitors

    This indicator has been updated and replaced by NICE indicator 322.

    Published
    21 August 2023

  12. Heart failure: beta blockers

    This indicator has been updated and replaced by NICE indicator 317.

    Published
    31 July 2019

  13. Heart Failure: ACEi or ARBs

    This indicator has been updated and replaced by NICE indicator 317.

    Published
    31 August 2019

  14. Weight management: BMI recording (long-term conditions)

    This indicator has been updated and replaced by NICE indicator 320.

    Published
    3 August 2015

  15. Asthma. Patient decision aid on asthma inhalers and climate change (BTS, NICE, SIGN)

    Asthma inhalers and climate change What is this decision aid about? Inhalers are a key part of treating your asthma. The most important thing is that...